TruSight Oncology 500 version 2 Analysis Overview Support Webinar Video
TruSight Oncology 500 is a next-generation sequencing tumor profiling assay that analyzes 523 genes for cancer-related biomarkers and supports the identification of DNA and RNA variants implicated in various tumor types, including measuring key immunotherapy biomarkers such as tumor mutation burden (TMB) and microsatellite instability (MSI). This webinar provides an overview of TruSight Oncology 500 analysis workflow and covered the following topics: how to assess biomarker (TMB and MSI) results, and options for data analysis and variant interpretation.
Video length: 46:45 min
For any feedback or questions regarding this article (Illumina Knowledge Article #8077), contact Illumina Technical Support techsupport@illumina.com. |
Last updated